Table 2.
Expression of CD28 and CTLA‐4 in T cells from RA patients and CS
| CS (n = 7) | Early RA (n = 14) | Chronic RA (n = 14) | Untreated RA (n = 7) | P | |
|---|---|---|---|---|---|
| CD3/CD4% | 32.6 (18.0‐57.6) | 30.6 (7.2‐47.4) | 33.8 (7.3‐46.1) | 33.4 (22.7‐44.2) | .753 |
| CD3/CD8% | 19.2 (10.4‐23.5) | 18.3 (2.2‐28.8) | 13.9 (2.2‐25.6) | 15.8 (6.8‐22.6) | .831 |
| CTLA4% CD4 | 0 (0‐0) | 0 (0‐1.5) | 0 (0‐0.1) | 0 (0‐0.3) | .783 |
| CTLA4MFI/CD4 | 0 (0‐3.9) | 0 (0‐14.4) | 0 (0‐6.3) | 0 (0‐3.6) | .901 |
| CTLA4% CD8 | 0 (0‐2.2) | 0 (0‐51.9) | 0 (0‐30.3) | 0 (0‐42) | .823 |
| CTLA4MFI/CD8 | 0.1 (0‐21.6) | 0 (0‐39.4) | 0.7 (0‐80) | 0 (0‐59.3) | .442 |
| CD28% CD4 | 93.7 (49.1‐98.4) | 93.3 (86.9‐96.7) | 91 (66.1‐99.2) | 95.9 (90.5‐99.5) | .741 |
| CD28MFI/CD4 | 345.4 (57.4‐764.8) | 345.9 (60.0‐701.2) | 410.5 (38.3‐1653) | 393.3 (123.8‐609.9) | .961 |
| CD28% CD8 | 64.9 (42.8‐89.7) | 58.4 (24.3‐85.9) | 42.7 (0.9‐82.6) | 60.8 (32.4‐91.0) | .029 |
| CD28MFI/CD8 | 132.0 (81.1‐212.3) | 61.3 (2.9‐319.5) | 33.1 (0‐113.2) | 61.2 (11.2‐285) | .015 |
The percentage of T cells positive and cell surface expression (MFI, mean fluorescence intensity) of CTLA‐4 and CD28 on peripheral blood mononuclear cells (PBMC) of RA patients and CS. The differences were determined by Kruskal‐Wallis test. Data are expressed as median (p5‐p95).
Abbreviations: CS, control subjects; RA, rheumatoid arthritis.